Radiopharmaceuticals Market Poised for Rapid Expansion to USD 16.6 Billion by 2032 – SNS Insider

Driven by personalized medicine, advanced imaging innovations, and rising chronic diseases, the sector is set for transformative growth.

AUSTIN, TX, UNITED STATES, February 20, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The Radiopharmaceuticals Market¹, valued at USD 5.0 billion in 2023, is on track to surge to USD 16.6 billion by 2032, growing at a robust CAGR of 10.4% over the forecast period 2024–2032. This impressive expansion is fueled by rapid technological advancements in healthcare, the rising prevalence of chronic diseases, and a notable shift towards personalized medicine. Radiopharmaceuticals, vital for diagnostic imaging and targeted therapies, are increasingly used to detect and treat conditions such as cancer, cardiovascular diseases, and neurological disorders.

Some of the factors driving the market growth include the growing usage of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging, the increase in cancer incidence worldwide, and the increasing use of theranostics in precision medicine. In addition, market growth is being driven by government initiatives to broaden nuclear medicine research as well as the growing need for novel radiopharmaceuticals for targeted therapy.

Get a Free Sample Report@ https://www.snsinsider.com/sample-request/1070

Key Players in Radiopharmaceuticals Market
• GE Healthcare
• Eckert & Ziegler
• PRECIRIX
• Curium Pharma
• Jubilant Pharmova Limited
• SOFIE
• Isotopia Molecular Imaging
• Bracco
• NorthStar Medical Radioisotopes
• Novartis AG
• Eczacibasi
• Fusion Pharmaceuticals Inc.
• Nihon Medi-Physics Co. Ltd
• The State Atomic Energy Corporation ROSATOM
• South African Nuclear Energy Corporation (Necsa)
• Cardinal Health
• Actinium Pharmaceuticals, Inc.
• Telix Pharmaceuticals Limited
• Lantheus
• Clarity Pharmaceuticals
• Bayer AG
• ITM Isotope Technologies Munich SE
• Eli Lilly and Company and others.

By Radioisotope, Technetium-99m Held the Largest Market Share of Around in 2023

the extensive utilization in diagnostic imaging in areas of cardiology, oncology, and neurology, technetium-99m remains the market leader. Due to its short half-life, affordable production cost, and excellent imaging characteristics, it is the radioisotope of choice for medical imaging. The demand for Technetium-99m is growing in hospitals and diagnostic centers around the globe, which is why major players like GE Healthcare and Curium are concentrating on expanding their Technetium-99m production and supply chain.

By Application, Cancer Segment Led the Market, Representing Around 32.5% in 2023.

The significant share of the cancer segment can be attributed to the increasing prevalence of cancer worldwide, as well as the growing need for nuclear medicine in diagnosis and treatment. The use of radiopharmaceuticals in the benefit of surgical oncology and preoperative medicine is tied back to the enhanced ability to detect rather indeterminate tumors earlier and more precisely by taking advantage of PET and SPECT imaging modalities. In addition, the clinical development of targeted radiopharmaceutical therapies, in particular lutetium-177 and actinium-225 based therapies, has exploded as they can be used to selectively kill off cancer while sparing normal surrounding tissues.

By End-User, Hospitals & Clinics Accounted for Around 34.9% of the Market in 2023

It is because consumption of radiopharmaceuticals catering diagnostic imaging and therapeutic applications majorly in oncology, cardiology and neurology. Increasing cancer and cardiovascular diseases have caused more demand for nuclear medicine procedures, mostly performed in hospitals and clinics, where advanced nuclear medicine imaging technologies (PET and SPECT) are equipped. Besides, availability of them has been supported by government funding due to increasing number of nuclear medicine department in hospitals and investment on healthcare infrastructure.

Buy Full Research Report on Radiopharmaceuticals Market 2024-2032 @ https://www.snsinsider.com/checkout/1070

North America Dominated the Market with a Share of 43.8 % in 2023

North America remains the leading region in the radiopharmaceuticals market, driven by the high adoption rate of nuclear medicine, advanced healthcare infrastructure, and strong research funding for radiopharmaceutical development. The presence of key players, such as Cardinal Health and Lantheus Medical Imaging, coupled with supportive regulatory policies, has fueled market growth. Additionally, increasing demand for precision medicine and targeted radiotherapy is expected to drive further expansion in the region.

Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Radiopharmaceuticals Market by Radioisotope
8. Radiopharmaceuticals Market by Application
9. Radiopharmaceuticals Market by Type
10. Radiopharmaceuticals Market by End User
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion

For further insights and customized research on the Radiopharmaceuticals Market, contact @ https://www.snsinsider.com/enquiry/1070

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Jagney Dave
SNS Insider Pvt. Ltd
+1 315 636 4242
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram

¹ https://www.snsinsider.com/reports/radiopharmaceuticals-market-1070